Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices
Portfolio Pulse from Vandana Singh
Boston Scientific Corporation (NYSE:BSX) reported strong Q3 earnings, with revenues and EPS surpassing expectations. The company raised its annual forecast due to strong demand for heart devices. BSX's cardiovascular segment saw significant growth, and the company projects continued sales and EPS growth for 2024. Analysts have a positive outlook on BSX, with an average price target indicating potential upside.
October 23, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific reported Q3 revenues of $4.21 billion, beating estimates, and raised its annual forecast due to strong demand for heart devices. The cardiovascular segment showed significant growth, and the company projects continued sales and EPS growth for 2024. Analysts have a positive outlook with a 7.71% upside potential.
Boston Scientific's strong Q3 performance, driven by high demand for heart devices, led to a raised annual forecast. The cardiovascular segment's growth and positive analyst outlook suggest a likely short-term price increase. The stock's current price action, despite being down, is overshadowed by the positive earnings report and future projections.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100